NICE expands access of Paxlovid to further 1.4 million Covid-19 patients
Expanded patient groups at risk of progression to severe Covid-19 will be eligible for Pfizer’s antiviral pill.
Expanded patient groups at risk of progression to severe Covid-19 will be eligible for Pfizer’s antiviral pill.
What's Your Reaction?
